BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has signed an exclusive worldwide license agreement. The agreement, which is part of its ongoing collaboration with the Max Planck Society and the University Medical Center Gottingen (“UMG”), outlines the development and commercialization of VHH antibodies (NanoAbs) targeting Interleukin-17 (“IL-17”) as treatments for all potential indications; the agreement notes that development will start with a focus on psoriasis and psoriatic arthritis. According to the announcement, BiondVax will lead out on the development and commercialization of the NanoAbs, with vivo proof-of-concept expected this year and in vivo anticipated early next year. The agreement adds to the company’s pipeline of biobetter antibodies targeting diseases with large unmet medical needs and represents attractive commercial opportunities. The announcement noted that recent preclinical in vivo data showed that BiondVax’s anti‑SARS‑CoV‑2 NanoAb prevented illness when inhaled prophylactically and led to a shorter, milder illness. “The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases but another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” said BiondVax Pharmaceuticals CEO Amir Reichman in the press release. “Psoriasis affects millions of people worldwide, and we believe our NanoAbs have the potential to provide a much-needed and vastly improved treatment option.”
To view the full press release, visit https://ibn.fm/NA8jf
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html